Anzeige
Mehr »
Login
Donnerstag, 02.07.2020 Börsentäglich über 12.000 News von 632 internationalen Medien
Mega-Treffer! Diese Silber-Rakete startet voll durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 855526 ISIN: JP3160400002 Ticker-Symbol: EII 
Frankfurt
02.07.20
15:34 Uhr
70,00 Euro
-1,00
-1,41 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
EISAI CO LTD Chart 1 Jahr
5-Tage-Chart
EISAI CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
68,5071,0020:25

Aktuelle News zur EISAI Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.06.Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea196TOKYO, June 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina...
► Artikel lesen
10.06.Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa234TOKYO, June 10, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel...
► Artikel lesen
04.06.Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons426TOKYO, June 4, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM" (pronounced "NOH-NOH", non- medical device)...
► Artikel lesen
EISAI Aktie jetzt für 0€ handeln
02.06.Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia300TOKYO, June 2, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for...
► Artikel lesen
01.06.BRIEF-Eisai Announces U.S. Availability Of DAYVIGO (lemborexant) CIV-
31.05.ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data5
29.05.AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody480Concerning the Dosage and Administration Related to the Indication of Hidradenitis SuppurativaTOKYO, May 29, 2020 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced an approval of partial...
► Artikel lesen
29.05.Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials335In Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual MeetingTOKYO, May 29, 2020 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth,...
► Artikel lesen
18.05.Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules224The first OTC product containing the same amount of stomach-protecting teprenone as for medical purposesTOKYO, May 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched New...
► Artikel lesen
14.05.Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting265TOKYO, May 14, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product...
► Artikel lesen
13.05.Eisai Co., Ltd. 2019 Q4 - Results - Earnings Call Presentation-
13.05.Eisai reports FY results-
27.04.Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine246TOKYO, Apr 27, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected as "Most Honored Company" and has been ranked first place overall in the Biotechnology & Pharmaceuticals...
► Artikel lesen
23.04.Japanese shares rise after 3 days of falls; Eisai slumps on drug delay6
01.04.Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China324TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613...
► Artikel lesen
27.03.XFRA DIVIDEND/INTEREST INFORMATION - 30.03.2020 - 12972FOLGENDE WERTPAPIERE WERDEN AM 27.03.2020 CUM DIVIDENDE/ZINSEN UND AM 30.03.2020 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 27.03.2020. THE EX-DIVIDEND/INTEREST...
► Artikel lesen
26.03.Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)365For Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaTOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application...
► Artikel lesen
25.03.Eisai's Discovery Research on Multikinase Inhibitor Lenvatinib Honored with PSJ Award for Drug Research and Development '20428TOKYO, Mar 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on lenvatinib mesylate (brand name: LENVIMA, lenvatinib), the orally available multikinase...
► Artikel lesen
23.03.Eisai to Launch Digital Tool "NouknowTM" in Japan for Regular Self-Assessment of Brain Performance (Brain Health)348TOKYO, Mar 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch "NouKNOWTM" (pronounced "NOH-NOH"), a new digital tool (non-medical device) for self-assessment of brain performance...
► Artikel lesen
19.03.Eisai: All-case Surveillance Condition for Approval of "Actonel 17.5 mg tablets" for Treatment of Paget's Disease of Bone Cleared in Japan271TOKYO, Mar 19, 2020 - (JCN Newswire) - EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has given notification of the results...
► Artikel lesen
Seite:  Weiter >>
88 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1